Antibiotic Prophylaxis in Oncological Surgery of Breast
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
Breast cancer is the most frequent malignancy in the female population Brazilian, except
non-melanoma skin tumors. Surgery plays an important role in regional spot disease control
and the definition of parameters for the adjuvant treatment indication. Surgical site
infections (SSI) are defined as wound infections occur following invasive procedures,
corresponding to 14-16% of all infections nosocomial in hospitalized patients, the most
common among patients surgical. SSIs should be examined as potential wound contamination
surgical, understood as the number of micro-organisms in the body and / or tissue being
operated. Considering this aspect, the cancer surgery breast are classified by their
potential for contamination by clean. The use of antibiotics to prevent the SSI in
mastectomies is not standardized in Handbook of National Health Surveillance Agency due to
the effectiveness of undocumented prophylaxis Thus the use of antibiotics may vary among
services. So this randomized clinical trial to evaluate the influence of the use of
Prophylactic antibiotics in SSI rates in oncological breast surgery.